Management of indolent lymphoma: Where are we now and where are we going

Blood Reviews

Volumn 26, Issue 6, 2012, Pages 279-288

  Lunning, Matthew A ^a   Vose, Julie M ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bendamustine; Bortezomib; Bruton's tyrosine kinase; CD20; Cyclophosphamide; Doxorubicin; Fludarabine; Follicular; Histone deacetylase inhibitors; Indolent lymphoma; Lenalidomide; Marginal zone; MTOR; Non Hodgkin; PI3K; Rituximab; Small lymphocytic

Indexed keywords

ALPHA INTERFERON; BENDAMUSTINE; BLEOMYCIN; BORTEZOMIB; CARFILZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; FOLINIC ACID; FOSTAMATINIB; IBRITUMOMAB TIUXETAN; IBRUTINIB; IDELALISIB; LENALIDOMIDE; METHOTREXATE; MITOXANTRONE; NAVITOCLAX; PREDNIMUSTINE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CLINICAL DECISION MAKING; CONSOLIDATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SUBSTITUTION; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; MOLECULAR TARGETED THERAPY; PROTEASOME INHIBITORS; STEM CELL TRANSPLANTATION;

EID: 84868201843     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2012.09.004     Document Type: Article

References (114)

1. Armitage J.O., Weisenburger D.D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998, 16(8):2780-2795.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
3. Mann R.B., Berard C.W. Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematol Oncol 1983, 1(2):187-192.
4. Anderson J.R., Armitage J.O., Weisenburger D.D. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998, 9(7):717-720.
5. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329(14):987-994.
6. Solal-Celigny P., Roy P., Colombat P., et al. Follicular lymphoma international prognostic index. Blood 2004, 104(5):1258-1265.
7. Buske C., Hoster E., Dreyling M., Hasford J., Unterhalt M., Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006, 108(5):1504-1508.
8. Federico M., Bellei M., Marcheselli L., et al. Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009, 27(27):4555-4562.
9. Portlock C.S., Rosenberg S.A. No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 1979, 90(1):10-13.
10. Horning S.J., Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984, 311(23):1471-1475.
11. Brice P., Bastion Y., Lepage E., et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997, 15(3):1110-1117.
12. Young R.C., Longo D.L., Glatstein E., Ihde D.C., Jaffe E.S., DeVita V.T. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988, 25(2 Suppl 2):11-16.
13. Ardeshna K.M., Smith P., Norton A., et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003, 362(9383):516-522.
14. Solal-Celigny P., Lepage E., Brousse N., et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998, 16(7):2332-2338.
15. Maloney D.G., Liles T.M., Czerwinski D.K., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994, 84(8):2457-2466.
16. Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15(10):3266-3274.
17. Maloney D.G., Grillo-Lopez A.J., White C.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90(6):2188-2195.
18. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16(8):2825-2833.
19. Feuring-Buske M., Kneba M., Unterhalt M., et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000, 79(9):493-500.
20. Davis T.A., White C.A., Grillo-Lopez A.J., et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999, 17(6):1851-1857.
21. Colombat P., Salles G., Brousse N., et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001, 97(1):101-106.
22. Hainsworth J.D., Litchy S., Burris H.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002, 20(20):4261-4267.
23. Hainsworth J.D., Litchy S., Barton J.H., et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003, 21(9):1746-1751.
24. Ardeshna K.M., Smith P., Qian W., Warden J., Stevens L., Pocock C.F., et al. An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a): A Preliminary Analysis. Blood 2010, 116:5. (Abstr #6).
25. Gandhi M.K., Marcus R.E. Follicular lymphoma: time for a re-think?. Blood Rev 2005, 19(3):165-178.
26. Czuczman M.S., Grillo-Lopez A.J., White C.A., et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17(1):268-276.
27. Czuczman M.S., Weaver R., Alkuzweny B., Berlfein J., Grillo-Lopez A.J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004, 22(23):4711-4716.
28. Hiddemann W., Kneba M., Dreyling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106(12):3725-3732.
29. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105(4):1417-1423.
30. Marcus R., Imrie K., Solal-Celigny P., et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008, 26(28):4579-4586.
31. Hiddemann W., Dreyling M., Unterhalt M. Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 2003, 30(1 Suppl 2):16-20.
32. Zinzani P.L., Magagnoli M., Bendandi M., et al. Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. Ann Oncol 2000, 11(3):363-365.
33. Frewin R., Turner D., Tighe M., Davies S., Rule S., Johnson S. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol 1999, 104(3):612-613.
34. Hendry L., Bowen A., Matutes E., Swansbury J., Catovsky D. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma. Leuk Lymphoma 2004, 45(5):945-950.
35. Velasquez W.S., Lew D., Grogan T.M., et al. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 2003, 21(10):1996-2003.
36. Tsimberidou A.M., McLaughlin P., Younes A., et al. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 2002, 100(13):4351-4357.
37. Hagenbeek A., Eghbali H., Monfardini S., et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol 2006, 24(10):1590-1596.
38. Leo E., Scheuer L., Schmidt-Wolf I.G., et al. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. Eur J Haematol 2004, 73(4):251-257.
39. Forstpointner R., Dreyling M., Repp R., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104(10):3064-3071.
40. Salles G., Seymour J.F., Offner F., et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377(9759):42-51.
41. Laszlo D., Galieni P., Raspadori D., et al. Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma 2000, 37(1-2):157-161.
42. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002, 128(11):603-609.
43. Heider A., Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001, 12(9):725-729.
44. Rummel M.J., Al-Batran S.E., Kim S.Z., et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005, 23(15):3383-3389.
45. Rummel M., Niederle N., Maschmeyer G., Banat A., von Gruenhagen U., Losem C., et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL. Blood 2009, (Abstr #405).
46. Nastoupil L., Sinha R., Byrtek M., Taylor M., Cerhan J.R., Friedberg J., et al. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States. Blood 2011, 118:47. (Abstr #97).
47. Schulz H., Bohlius J.F., Trelle S., et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007, 99(9):706-714.
48. Witzig T.E., Fishkin P., Gordon L.I., et al. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma 2011, 52(7):1188-1199.
49. Press O.W., Unger J.M., Braziel R.M., et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006, 24(25):4143-4149.
50. Press O.W., Unger J.M., Rimsza L.M., Friedberg J., LeBlanc M., Czuczman M.S., et al. A phase III randomized intergroup trial (SWOG S0016) of CHOP chemotherapy plus rituximab vs. CHOP chemotherapy plus iodine-131-tositumomab for the treatment of newly diagnosed follicular non-Hodgkin's lymphoma. Blood 2011, 118:48. (Abstr #98).
51. Hainsworth J.D., Litchy S., Shaffer D.W., Lackey V.L., Grimaldi M., Greco F.A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005, 23(6):1088-1095.
52. van Oers M.H., Klasa R., Marcus R.E., et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108(10):3295-3301.
53. Ghielmini M., Schmitz S.F., Cogliatti S., et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005, 23(4):705-711.
54. Martinelli G., Schmitz S.F., Utiger U., et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010, 28(29):4480-4484.
55. Hochster H., Weller E., Gascoyne R.D., et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009, 27(10):1607-1614.
56. Nastoupil L., Sinha R., Byrtek M., Zhou X., Taylor M., Cerhan J.R., et al. Characteristics and effectiveness of rituximab (R) maintenance regimens among US patients diagnosed with follicular lymphoma (FL) 2004-2007. Blood 2011, 118:1584. (Abstr #3708).
57. Kahl B., Hong F., Williams M.E., Gascoyne R.D., Wagner L.I., Drauss J.C., et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood 2011, (Abstr #LBA6).
58. Colombat P., Donadio D., Fouillard L., et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant 1994, 13(2):157-162.
59. Cervantes F., Shu X.O., McGlave P.B., et al. Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1995, 16(3):387-392.
60. Bierman P.J., Vose J.M., Anderson J.R., Bishop M.R., Kessinger A., Armitage J.O. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997, 15(2):445-450.
61. Freedman A.S., Neuberg D., Mauch P., et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999, 94(10):3325-3333.
62. Apostolidis J., Gupta R.K., Grenzelias D., et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000, 18(3):527-536.
63. Brice P., Simon D., Bouabdallah R., et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 2000, 11(12):1585-1590.
64. Horning S.J., Negrin R.S., Hoppe R.T., et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001, 97(2):404-409.
65. Lenz G., Dreyling M., Schiegnitz E., et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004, 22(24):4926-4933.
66. Sebban C., Mounier N., Brousse N., et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006, 108(8):2540-2544.
67. Montoto S., Canals C., Rohatiner A.Z., et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007, 21(11):2324-2331.
68. Rohatiner A.Z., Nadler L., Davies A.J., et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007, 25(18):2554-2559.
69. Vose J.M., Bierman P.J., Loberiza F.R., et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 2008, 14(1):36-42.
70. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003, 21(21):3918-3927.
71. Ladetto M., De Marco F., Benedetti F., et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008, 111(8):4004-4013.
72. van Besien K.W., Khouri I.F., Giralt S.A., et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 1995, 13(5):1096-1102.
73. Verdonck L.F., Dekker A.W., Lokhorst H.M., Petersen E.J., Nieuwenhuis H.K. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997, 90(10):4201-4205.
74. van Besien K., Sobocinski K.A., Rowlings P.A., et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998, 92(5):1832-1836.
75. van Besien K., Loberiza F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003, 102(10):3521-3529.
76. Khouri I.F., Saliba R.M., Giralt S.A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001, 98(13):3595-3599.
77. Kusumi E., Kami M., Kanda Y., et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 2005, 36(3):205-213.
78. Vigouroux S., Michallet M., Porcher R., et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007, 92(5):627-634.
79. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111(12):5530-5536.
80. Khouri I.F., Saliba R.M., Erwin W.D., et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 2012, 119(26):6373-6378.
81. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23(4):667-675.
82. O'Connor O.A. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma 2005, 6(3):191-199.
83. Di Bella N., Taetle R., Kolibaba K., et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 2010, 115(3):475-480.
84. Gerecitano J., Portlock C., Hamlin P., et al. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clin Cancer Res 2011, 17(8):2493-2501.
85. Coiffier B., Osmanov E.A., Hong X., et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011, 12(8):773-784.
86. Matous J., Letzer J., Rosen S., Noga N., Fowler S., Smith B., et al. Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study. J Clin Oncol 2009, 27:15s. (suppl; abstr 8550).
87. Fowler N., Kahl B.S., Lee P., et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol 2011, 29(25):3389-3395.
88. Friedberg J.W., Vose J.M., Kelly J.L., et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011, 117(10):2807-2812.
89. Sehn L.H., MacDonald D., Rubin S., et al. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2011, 29(25):3396-3401.
90. de Jong D., Fest T. The microenvironment in follicular lymphoma. Best Pract Res Clin Haematol 2011, 24(2):135-146.
91. Smith S.M., Grinblatt D., Johnson J.L., et al. Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol 2008, 140(3):313-319.
92. Chanan-Khan A., Miller K.C., Musial L., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006, 24(34):5343-5349.
93. Wiernik P.H., Lossos I.S., Tuscano J.M., et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008, 26(30):4952-4957.
94. Witzig T.E., Wiernik P.H., Moore T., et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009, 27(32):5404-5409.
95. Dutia M., DeRoock I., Chee K., O'donnell R., Quirch C., Reed-Pease C., et al. R2: Preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent non-Hodgkin's lymphoma. Blood 2009, 114:670. (Abstr #1679).
96. Fowler N.H., McLaughlin P., Kwak F., Hagemeister M., Fanale L., Fayad B., et al. Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:15s. (Suppl.; abstr 8548).
97. Samaniego F., HF, McLaughlin P., Kwak L.W., Romaguera J., Fanale M.A., et al. High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol 2011, 29. (Suppl.; abstr 8030).
98. Leonard J., Jung S.H., Johnson J.L., Barlett N., Blum K.A., Cheson B.D. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol 2012, 30. (Suppl.; abstr 8000).
99. Friedberg J.W., Sharman J., Sweetenham J., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115(13):2578-2585.
100. Fowler N.H., Porte-Sharman J., Smith S.M., Boyd T., Grant B., Kolibaba K.S., et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study. Blood 2010, 116:425. (Abstr #964).
101. Byrd J.C., Blum K.A., Burger J.A., Coutre S.E., Sharman J.P., Furman R.R., et al. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): interim results of a phase Ib/II study. J Clin Oncol 2011, 29. (Suppl.; abstr 6508).
102. Byrd J.C., Furman R.R., Coutre S.E., Andreas-Burger J., Blum K.A., Porter-Sharman J., et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): interim results of a phase Ib/II study. J Clin Oncol 2012, 30. (Suppl.; abstr 6507).
103. Kahl B.S., Byrd J.C., Flinn I.W., Wagner-Johnson N., Spurgeon S., Benson D.M., et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ. In patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010, 116:741. (Abstr #1777).
104. Furman R.R., Barrientos J.C., Porter-Sharman J., De Vos S., Leonard J., Coutre S.E., et al. A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol 2012, 30. (Suppl.; 1139 abstr 6518).
105. Tobinai K., Ogura M., Maruyama D., et al. Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. Int J Hematol 2010, 92(4):563-570.
106. Witzig E., Habermann T., Reeder C., Micallef I., Ansell S., Porrata L., et al. A phse II trial of the oral MTOR inhibitor everolimus in relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease. Haematologica 2009, 94(Suppl. 2). (436 abs. 1081).
107. Bhende P.M., Park S.I., Lim M.S., Dittmer D.P., Damania B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 2010, 24(10):1781-1784.
108. Wilson W.H., O'Connor O.A., Czuczman M.S., et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010, 11(12):1149-1159.
109. Duvic M., Talpur R., Ni X., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109(1):31-39.
110. O'Connor O.A., Pro B., Pinter-Brown L., et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011, 29(9):1182-1189.
111. Kelly W.K., Richon V.M., O'Connor O., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9(10 Pt 1):3578-3588.
112. Watanabe T., Kato H., Kobayashi Y., et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 2010, 101(1):196-200.
113. Kirschbaum M., Frankel P., Popplewell L., et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011, 29(9):1198-1203.
114. Blum K.A., Liu Z., Lucas D.M., et al. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol 2010, 150(2):189-195.